Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?
Authors
Keywords
-
Journal
EPMA Journal
Volume 3, Issue 1, Pages -
Publisher
Springer Nature
Online
2012-01-11
DOI
10.1007/s13167-011-0138-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- When is active surveillance the appropriate treatment for prostate cancer?
- (2011) Peter C. Albertsen ACTA ONCOLOGICA
- Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients
- (2011) G. Attard et al. CLINICAL CANCER RESEARCH
- The changing therapeutic landscape of castration-resistant prostate cancer
- (2011) Timothy A. Yap et al. Nature Reviews Clinical Oncology
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Utilizing circulating tumor cells: challenges and pitfalls
- (2010) Gerhardt Attard et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
- (2009) G. Attard et al. CANCER RESEARCH
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
- (2009) Howard I Scher et al. LANCET ONCOLOGY
- Mortality Results from a Randomized Prostate-Cancer Screening Trial
- (2009) Gerald L. Andriole et al. NEW ENGLAND JOURNAL OF MEDICINE
- Screening and Prostate-Cancer Mortality in a Randomized European Study
- (2009) Fritz H. Schröder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
- (2008) D. Olmos et al. ANNALS OF ONCOLOGY
- Fusion in the ETS gene family and prostate cancer
- (2008) S A Narod et al. BRITISH JOURNAL OF CANCER
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
- (2008) Steven J. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now